Table 1.

Baseline Patient Characteristics (n = 212)

Characteristic	Value
Age, y (Median, Range)	59 (28–90)
Sex
Female	123 (58%)
Male	89 (42%)
Race
Caucasian	177 (83%)
African American	32 (15%)
Other	3 (2%)
Disease status
Metastatic	162 (76%)
Locally advanced	50 (24%)
Eastern Cooperative Oncology Group performance status
0–1	196 (92%)
≥2	6 (8%)
Regimen received
Gemcitabine/cisplatin/5-fluorouracil23	47 (22%)
Gemcitabine/5-fluorouracil/bevacizumab20	43 (20%)
Gemcitabine/cisplatin21	42 (20%)
Gemcitabine/etanercept25	37 (18%)
Gemcitabine/cisplatin/celecoxib24	22 (10%)
Gemcitabine/docetaxel/capecitabine22	21 (10%)